There are three main subtypes and they’re grouped by three genetic markers your doctor will look for on a biopsy specimen: ...

October is Breast Cancer Awareness Month, and CURE is here to address some of the most common questions patients have after a ...

Elissa Kalver was diagnosed with HER2-positive metastatic breast cancer at 34. Since then, she has founded a nonprofit and ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu ...

Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD Enhertu is a treatment for HER2-low breast cancer that extends your life expectancy more than chemotherapy. A doctor gives Enhertu ...

Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With ...

Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial Human epidermal ...

Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer PURPOSE: Few studies have examined the ...

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with ...

In an interview with Targeted Oncology, Gerrina Ruiter, MD, PhD, Netherlands Cancer Institute and study investigator, explains the rationale and design of the Beamion LUNG-1 study, highlights the ...

– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...